Amgen, Inc. (AMGN): Huge Upside on Pipeline Strength
Amgen, Inc. (NASDAQ:AMGN) is the world’s largest independent biotechnology company.
Posts Tagged ‘NASDAQ:AMGN’
Gilead Sciences, Inc. (GILD), American International Group, Inc. (AIG): The Biggest Companies That Don’t Pay Dividends — But May Be About To
The S&P 500 fell nearly 10% in June 2008, and investors began to brace for an eventual market crash later in the year.
Amgen, Inc. (AMGN), Apple Inc. (AAPL), Coach, Inc. (COH): Three Attractive, Future Dividend Achievers
I regularly browse through a current list of components within the dividend achiever index (companies with 10 or more years of consecutive dividend increases) for new investment...
Dynavax Technologies Corporation (DVAX), Elan Corporation, plc (ADR) (ELN): This Week in Biotech
With the SPDR S&P Biotech Index up 29% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Amgen, Inc. (AMGN), Bristol Myers Squibb Co. (BMY): Ovarian Cancer Drug Half Way There
The biotech giant announced today that its cancer drug trebananib combined with chemotherapy paclitaxel extended median progression-free survival in recurrent ovarian cancer patients...
Two More Good Reasons to Buy Celgene Corporation (CELG)
Celgene Corporation (NASDAQ:CELG) shares have soared more than 46% so far in 2013.
Merck & Co., Inc. (MRK), Pfizer Inc. (PFE): Does This Pipeline Promise Tomorrow’s Blockbuster Sales?
Nearly every big pharma player has been hit with patent expirations that have hit hard on sales lately, and Merck & Co., Inc. (NYSE:MRK) is no exception. Merck & Co., Inc.
Pfizer Inc. (PFE), Merck & Co., Inc. (MRK): Where to Invest for More Health-Care Exposure
You have plenty of choices of where to invest your portfolio.
Regeneron Pharmaceuticals Inc (REGN), Amgen, Inc. (AMGN), Gilead Sciences, Inc. (GILD): Is College Debt a Drag on These Promising Healthcare Stocks
Some stocks seem to have all the luck, offering the best of both worlds.
Amgen, Inc. (AMGN): The Ultimate Biotech Diversification Strategy
You want to invest in biotech. You hear about all the monstrous pops and mini-fortunes that are built overnight.
Amgen, Inc. (AMGN): Insiders Aren’t Crazy About It
Amgen, Inc. (NASDAQ:AMGN) was in 36 hedge funds' portfolio at the end of the first quarter of 2013.
Do Hedge Funds and Insiders Love Celgene Corporation (CELG)?
Celgene Corporation (NASDAQ:CELG) was in 44 hedge funds' portfolio at the end of the first quarter of 2013.
Amgen, Inc. (AMGN) Stock Checkup for May
I have jokingly referred to Amgen, Inc. (NASDAQ:AMGN) in the past as a "senior citizen" of biotech. The company was founded 33 years ago, making Amgen, Inc.
Hedge Funds Are Betting On Gilead Sciences, Inc. (GILD)
To the average investor, there are a multitude of indicators market participants can use to watch stocks.
Amgen, Inc. (AMGN), Bristol Myers Squibb Co. (BMY): Can Financial Innovation Unlock a Cure for Cancer?
A few years ago, Andrew W. Lo from the MIT Sloan School of Management gave a lengthy talk at a meet-and-greet for prospective students of the Master of Finance program.
Amgen, Inc. (AMGN), Johnson & Johnson (JNJ): Boom Or Ticking Time Bomb?
Reaching the coveted $1 billion mark in annual sales is no small feat for a drug.
Amgen, Inc. (AMGN), Duke Energy Corp (DUK), And Where To Find Growth
When a new strategy hits the Street and it gains assets at a significant rate over a very short period of time, the ability of this new program to absorb the new money is quickly...
Amgen, Inc. (AMGN): What’s Its Next Catalyst?
Amgen, Inc. (NASDAQ:AMGN) stock has been on a bit of a roller coaster lately.
Amgen, Inc. (AMGN), Cytokinetics, Inc. (CYTK): A New Approach to Treating a Broken Heart
A failing heart is a lot like a glass Heinz Ketchup bottle. Squeezing the bottle isn't very efficient, so you smack that strategically placed '57,' and still no condiment. ...
Amgen, Inc. (AMGN): Is It a Buy Now?
When it comes to biotechs, Amgen, Inc. (NASDAQ:AMGN) qualifies for the senior citizen discount.
Amgen, Inc. (AMGN): Can Earnings Keep It Soaring?
On Tuesday, Amgen, Inc. (NASDAQ:AMGN) will release its latest quarterly results.
Amgen, Inc. (AMGN): Is It Too Hot to Handle?
Shares of Amgen, Inc. (NASDAQ:AMGN) have returned over 65% in the past year; 109% if dividends are included. The S&P 500 has returned just over 13%.
Under The Hood: An Unheralded Biotech ETF – iShares NASDAQ Biotechnology Index (IBB)
Another day, another set of fresh all-time highs for the major biotechnology ETFs.
Amgen, Inc. (AMGN), Regeneron Pharmaceuticals Inc (REGN), NPS Pharmaceuticals, Inc. (NPSP): Can These Biotechs Continue to Climb?
Two high-flying biotech stocks of late are NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) .
Biopharma News: Theravance Inc (THRX), VIVUS, Inc. (VVUS), Amgen, Inc. (AMGN)
Editor's Note: Related tickers: Theravance Inc (NASDAQ:THRX), VIVUS, Inc. (NASDAQ:VVUS), Amgen, Inc.
Amgen, Inc. (AMGN), Celgene Corporation (CELG) & More Biotech Madness!
March Madness is well under way with the Final Four taking place this weekend.
Amgen, Inc. (AMGN), Merck & Co., Inc. (MRK): Can It Field a Psoriasis Blockbuster?
Targeting psoriasis, rheumatoid arthritis, and other immune diseases has created some massive markets over the last decade.
Rigel Pharmaceuticals, Inc. (RIGL): Why This Stock Is Poised to Bounce Back
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, clinical-stage drug development company ...
Amgen, Inc. (AMGN): The One Biotech Stock Buffett Should Buy
The biotechnology sector can be a land of immense spoils and incredible heartbreak.
Johnson & Johnson (JNJ): This Company’s Biggest Drug Rivals
What doesn't J&J produce? From pharmaceuticals to consumer care goods to medical devices, this major medical player has it all.
Bristol Myers Squibb Co. (BMY), Amgen, Inc. (AMGN): Tackling Cancer: Melanoma’s Biggest Current & Upcoming Players
As I noted five weeks ago, cancer statistics are both staggering and disappointing.
Is Amgen, Inc. (NASDAQ:AMGN) Going to Burn These Hedge Funds?
Amgen, Inc. (NASDAQ:AMGN) was in 28 hedge funds' portfolio at the end of the fourth quarter of 2012.
Amgen, Inc. (AMGN), Affymax, Inc. (AFFY): The Danger of the One-Hit Wonder
The drug development field is a potentially lucrative, although always dangerous area for small companies and their investors to participate in.
Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Is Amgen, Inc. (AMGN) a Cash King?
In this series, we'll highlight four companies in an industry, and compare their "cash king margins" over time, trying to determine which has the greatest likelihood of putting...
Amgen, Inc. (AMGN), Bristol Myers Squibb Co. (BMY): Is Merck & Co., Inc. (MRK)’s Type 2 Diabetes Blockbuster in Trouble?
For the last several years, Merck & Co., Inc.
Does Amgen, Inc. (AMGN)’s Dividend Have Room to Soar?
With interest rates still sitting near record lows, investors looking for current income have been forced to move from fixed-income positions and into stocks to find yield.
Should I Buy AstraZeneca plc (ADR) (AZN) for My ISA: GlaxoSmithKline plc (ADR) (GSK), Amgen, Inc. (AMGN)
LONDON -- You have only a few weeks to use your ISA allowance before the April 5 deadline, so don't fluff this great tax-saving opportunity.
Smooth-Ride Investments: The Home Depot, Inc. (HD), Amgen, Inc. (AMGN), Johnson & Johnson (JNJ)
After the stomach-churning market drop of several years ago and the equally impressive climb back from 2009's lows, many investors are feeling a bit exhausted.
Is DaVita HealthCare Partners Inc (DVA) Worth a Buy?
In order to be successful in investing, just pick a great company and stick with it through ups and downs. That is what Charlie Munger often advises investors to do.
Is Bristol-Myers Squibb Co. (BMY) One of the Best Companies in America?
The Motley Fool recently published its list of The 25 Best Companies in America and while Bristol-Myers Squibb Co.
3 Potential Game-Changing Cancer Drugs: Amgen, Inc. (AMGN), Merck & Co., Inc. (MRK), ZIOPHARM Oncology Inc. (ZIOP)
Cancer just might be one of the scariest words in the English language. What goes through your mind when you hear that someone close to you has cancer? Sadness, probably.
3 Can’t-Miss Health-Care Events This Week: Synageva BioPharma Corp (GEVA), Amedisys Inc (AMED), Gentiva Health Services, Inc. (GTIV)
You won't often hear me say this, but it's a pretty quiet week on the health-care front.
Another Record High? Not for Exxon Mobil Corporation (XOM), Amgen Inc. (AMGN), Rite Aid Corporation(RAD)
For three days running, the Dow Jones Industrials have set new all-time record highs.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Is There a “First-Mover” Advantage in Biotech?
The early bird gets the worm. Business gurus might not use that old phrase, but many of them tout the principle behind it.
Pfizer Inc. (PFE), Amgen, Inc. (AMGN), Merck & Co., Inc. (MRK): Why Wouldn’t You Buy These Pharmaceutical Stocks?
Investors are always trying to find the right balance between risk andreward.
2 Sides of Celgene Corporation (CELG)’s Apremilast Results
Celgene Corporation (NASDAQ:CELG) has good news -- and it has bad news.
Why Investors Should Love Celgene Corporation (CELG)’s Apremilast
Celgene Corporation (NASDAQ:CELG) shareholders didn't have to wait long for good news in 2013. On Jan.
